Metoprolol as a universal β-blocker: sample clinical scenarios Case reports

Article Sidebar

PDF (Język Polski)


Published: Dec 31, 2020
Keywords:
metoprolol CR/XL, dosage, diseases of the cardiovascular system

Main Article Content

Michał Grabysa
Oddział Chorób Wewnętrznych i Gastroenterologii, SPZOZ MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie
Agata Tomaszewska
Oddział Chorób Wewnętrznych i Gastroenterologii, SPZOZ MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie
Radosław Grabysa
Oddział Chorób Wewnętrznych i Gastroenterologii, SPZOZ MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie. 2. Katedra Pulmonologii, Szkoła Zdrowia Publicznego, Uniwersytet Warmińsko-Mazurski w Olsztynie

Abstract

Metoprolol, a highly cardioselective beta-blocker without intrinsic sympathomimetic activity, continues to play an important role in current treatment guidelines for hypertension, chronic heart failure, and coronary artery disease. Experts pay special attention to its modern, slow-release pharmaceutical form in the form of succinate, thoroughly tested in a number of clinical trials. Metoprolol succinate can be used in a single daily dose which ensures high compliance. The paper presents typical clinical scenarios in which appropriately dosed metoprolol CR/XL should be used. It should be emphasized that metoprolol CR/XL has the most registration indications among all the original β-blockers.

Downloads

Download data is not yet available.

Article Details

How to Cite
Grabysa , M., Tomaszewska , A., & Grabysa , R. (2020). Metoprolol as a universal β-blocker: sample clinical scenarios. Cardiology in Practice, 14(3-4), 26-33. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1165
Issue
Vol 14 No 3-4 (2020)
Section
Clinical pharmacology in practice
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159): 1736-88.
2. Braunwald E. Cardiovascular pharmacology: a look back and a glimpse into the future. Eur Heart J Cardiovasc. Pharmacother. 2015; 1: 7-9.
3. Dąbrowski R. Antagoniści układu adrenergicznego. In: Kardiologia. Podręcznik Polskiego Towarzystwa Kardiologicznego. Via Medica, Gdańsk 2019.
4. Williams B, Mancia G, Desormais I et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens. 2018; 36: 1953-2041.
5. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-86.
6. Ponikowski P, Voors A, Anker S et al. Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol Pol. 2016; 74(10): 1037-147.
7. Montalescot G, Sechtem U, Achenbach S et al. Wytyczne ESC dotyczące postępowania w stabilnej chorobie wieńcowej w 2013 roku. Kardiol Pol. 2013; 71(suppl X): 243-318.
8. Charakterystyka produktu leczniczego Betaloc ZOK, 02.2017.
9. Hjalmarson A, Goldstein S, Fagerberg B et al. MERIT-HF Study Group: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MER-IT-HF). JAMA. 2000; 283: 1295-130.
10. Fonarow GC, Abraham WT, Albert NM et al. Dosing of Beta-Blocker Therapy Before, During, and After Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure). Am J Cardiol. 2008; 102: 1524-9.
11. Bhatt AS, DeVore AD, DeWald TA et al. Achieving a Maximally Tolerated b-Blocker Dose in Heart Failure Patients Is There Room for Improvement? J Am Coll Cardiol. 2017; 69(20): 2542-50.
12. Filipiak KJ, Opolski G. Działania niepożądane i środki ostrożności przy stosowaniu leków beta-adrenolitycznych – spojrzenie z perspektywy 2005 roku. Choroby Serca i Naczyń. 2005; 2(3): 157-16.
13. Wikstrand J, Wedel H, Castagno D et al. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med. 2014; 275: 134-43.
14. Ruwald AC, Gislason GH, Vinther M et al. Importance of beta-blocker dose in prevention of ventricular tachyaarythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study. Europace. 2018; 20: f217-24.
15. Van Veldhuisen DJ, Aass H, El Allaf D et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MER-IT-HF Study. Eur J Heart Fail. 2006; 8: 539-54.
16. Kühlkamp V, Schirdewan A, Stangl K et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2000; 36(1): 139-46.